Cheap Broker Fees
Ligand Pharmaceuticals Incorporated (LGND) is a leading biotechnology business based in the US. It opened the day at USD$135.85 after a previous close of USD$135.93. During the day the price has varied from a low of USD$133.13 to a high of USD$135.85. The latest price was USD$133.25 (25 minute delay). Ligand Pharmaceuticals is listed on the NASDAQ and employs 155 staff. All prices are listed in US Dollars.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Since the stock market crash in March caused by coronavirus, Ligand Pharmaceuticals's stock price has had significant positive movement.
Its last market close was $136.29, which is 26.09% up on its pre-crash value of $100.73 and 138.10% up on the lowest point reached during the March crash when the stocks fell as low as $57.24.
If you had bought $1,000 worth of Ligand Pharmaceuticals stocks at the start of February 2020, those stocks would have been worth $787.93 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,522.36.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|52-week range||$78.26 - $219.75|
|50-day moving average||$134.30|
|200-day moving average||$128.43|
|Wall St. target price||$207.86|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$2.89|
|1 week (2021-10-14)||N/A|
|1 month (2021-09-21)||N/A|
|3 months (2021-07-23)||9.22%|
|6 months (2021-04-23)||-8.87%|
|1 year (2020-10-23)||56.73%|
|2 years (2019-10-25)||19.69%|
|3 years (2018-10-25)||168.87|
|5 years (2016-10-25)||42.83%|
Valuing Ligand Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ligand Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Ligand Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 47x. In other words, Ligand Pharmaceuticals shares trade at around 47x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Ligand Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.9849. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Ligand Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Ligand Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $77.6 million.
The EBITDA is a measure of a Ligand Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$251.7 million|
|Operating margin TTM||13.87%|
|Gross profit TTM||$96.6 million|
|Return on assets TTM||1.75%|
|Return on equity TTM||6.47%|
|Market capitalisation||$2.3 billion|
TTM: trailing 12 months
There are currently 1.7 million Ligand Pharmaceuticals shares held short by investors – that's known as Ligand Pharmaceuticals's "short interest". This figure is 2.4% down from 1.8 million last month.
There are a few different ways that this level of interest in shorting Ligand Pharmaceuticals shares can be evaluated.
Ligand Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Ligand Pharmaceuticals shares currently shorted divided by the average quantity of Ligand Pharmaceuticals shares traded daily (recently around 351800.40567951). Ligand Pharmaceuticals's SIR currently stands at 4.93. In other words for every 100,000 Ligand Pharmaceuticals shares traded daily on the market, roughly 4930 shares are currently held short.
However Ligand Pharmaceuticals's short interest can also be evaluated against the total number of Ligand Pharmaceuticals shares, or, against the total number of tradable Ligand Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ligand Pharmaceuticals's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Ligand Pharmaceuticals shares in existence, roughly 100 shares are currently held short) or 0.1461% of the tradable shares (for every 100,000 tradable Ligand Pharmaceuticals shares, roughly 146 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Ligand Pharmaceuticals.
We're not expecting Ligand Pharmaceuticals to pay a dividend over the next 12 months.
Ligand Pharmaceuticals's shares were split on a 1:6 basis on 18 November 2010. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Ligand Pharmaceuticals shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Ligand Pharmaceuticals shares which in turn could have impacted Ligand Pharmaceuticals's share price.
Over the last 12 months, Ligand Pharmaceuticals's shares have ranged in value from as little as $78.26 up to $219.75. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ligand Pharmaceuticals's is 1.0878. This would suggest that Ligand Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for the treatment of osteoporosis; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of PPD; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney, and other diseases. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in Emeryville, California. .
ProShares Bitcoin Strategy ETF is the first fund tied to the value of a cryptocurrency to trade on the major U.S. markets. Here’s how to invest if you’re in Singapore.
What you need to know about investing in Bucket Studio from Singapore.
Learn how to stake AVAX tokens and earn rewards by supporting the Avalanche blockchain.
True to its name, SuperRare is an NFT marketplace that focuses on crypto art tokenised on the Ethereum blockchain. The result is part marketplace and part social network for the artistic side of the NFT community.
Find out how a Web 3.0 wallet can allow you to access the world of DeFi, plus discover which wallets we recommend.
What you need to know about investing in Evergrande from Singapore.
Buy and sell unique digital assets on the largest NFT marketplace in the crypto space.
Find out how to stake your THETA tokens and how Theta’s multi-BFT proof-of-stake consensus mechanism works.
DeFi tokens compose a prominent sector in the cryptocurrency markets. Learn the basics of these tokens here.
If you are looking to start buying, selling and trading NFTs, Mintable is one of the best places to start.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.